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Background: Focal adhesion Kinase (FAK) is a nonreceptor protein tyrosine kinase that is overexpressed in tumors
and plays a significant role in tumor survival and metastasis. The purpose of the study is to perform correlation of
FAK expression with patient prognostic factors using tissue microarrays (TMA) samples.
Methods: We analyzed FAK expression by immunohistochemical staining in 196 breast primary tumor samples
from stage II-IV patients and in 117 metastatic tissues matched to the primary tumors using TMA that were stained
with FAK monoclonal antibody.
Results: High FAK expression in primary tumors was associated with a younger age of patients (p = 0.033),
lymphovascular invasion (p = 0.001) and with the triple-negative phenotype (p = 0.033). FAK expression in 117
metastatic tissues positively correlated with FAK expression in matched primary tumors by Spearman correlation
analysis. In addition, a strong positive correlation was observed between high FAK expression and shorter overall
survival and progression free survival in patients with metastatic tumors.
Conclusions: The data demonstrate a high potential for FAK as a therapeutic target, especially in triple-negative
breast cancer patients with high FAK expression.
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Focal Adhesion Kinase (FAK) is a 125 kDa non receptor
kinase which localizes at the focal adhesion sites and is
important for tumor survival, metastasis and angiogenesis
[1-3]. FAK was shown to be overexpressed in many types
of tumors: colon [4], thyroid [5], pancreatic [6], ovarian
[7], brain cancer [8], neuroblastoma [9], oral cancer [10],
and others. FAK was shown to be associated with an
aggressive phenotype in breast cancer tumors [11] and to
be overexpressed at early stages of breast tumorigenesis
[12], suggesting that FAK expression precedes invasion
and metastasis, which is necessary for tumor survival
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article, unless otherwise stated.In a previous report evaluating FAK levels in 629 breast
tumor samples from patients with mostly Stage I or II
breast cancer, 25% had high FAK expression, while
approximately 75% were classified as having not high FAK
levels (11). Those with high FAK expression were noted to
have significant associations with poor prognostic features
such as higher mitotic index, higher grade, estrogen recep-
tor (ER) and progesterone receptor (PR) negativity, as
well as HER-2 overexpression. In the present report, we
analyzed FAK expression in 196 stage II-IV breast cancer
patients and 117 metastatic samples available matched to
the primary tumors using the tissue microarray (TMA)
technique which allowed us to analyze hundreds of tissue
samples simultaneously using one paraffin block, reducing
variability between samples in the case of regular immu-
nohistochemical staining of many samples of large tumor
sections [13]. The purpose of this study was to define a
method for quantifying FAK levels in TMA breast tissueentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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factors associated with high FAK expression in more
advanced primary and metastatic breast tumor samples.Table 1 Characteristics of breast cancer patients analyzed
for FAK staining using TMAMethods
Tumor samples
Breast cancer tumor samples were collected and all cases
of breast cancer diagnosed between November 1994 and
January 2008 treated surgically at Roswell Park Cancer
Institute (RPCI), Buffalo, NY. Samples were frozen imme-
diately in liquid nitrogen, and other tissue available from
blocks fixed in paraffin. Medical records were reviewed
to define clinical and pathological characteristics of all
cases with tumor samples used for the study. The Roswell
Park Cancer Institute Institutional Review Board (IRB)
approved this research and approval is consistent with
federal, state and local requirements. The clinical and
outcome data were de-identified.Characteristic Number (%)
Number of cases 196
Age (median) 56 (range 27-91)
Positive lymph nodes (median) 4 (range 0-45)
Histological grade
Grade I (well differentiated) 7 (3.7%)
Grade II (moderately differentiated) 36 (19.1%)
Grade III (poorly differentiated) 145 (77.1%)
Stage
Stage IIA 58 (29.7%)
Stage IIB 75 (38.5%)
Stage IIIA 23 (11.8%)
Stage IIIB 26 (13.3%)Tissue microarrays (TMA)
TMA’s were constructed from formalin-fixed paraffin
tissues with tumors grouped based on hormone receptor
and HER-2 status. TMA’s containing breast cancer tumors
from 196 breast tumor samples were prepared with each
tumor in triplicate. Among these samples, 117 samples
included tissue from the primary breast tumor and from
matched metastatic tumor tissue. Three one-millimeter
tissue cores from formalin-fixed paraffin embedded donor
blocks were precisely arrayed into a new recipient paraffin
block that included tumor specimens and controls, which
included multiple cores of normal tissue from 10 different
organs. Each patient had three breast tumor tissue cores
on a single TMA slide.Stage IIIC 4 (2.1%)















Yes 93 (50.5%)Immunohistochemical staining
The immunohistochemical staining was performed with
FAK 4.47 antibody (Millipore #05-537). For antigen
retrieval, slides were heated in the microwave for
10 minutes in citrate buffer (pH 6.0), followed by a
15 minute cool period. Endogenous peroxidase was
quenched with aqueous 3% H2O2 for 10 minutes and
washed with 1×PBS with 0.5% Tween 20 solution.
Slides were loaded on a DAKO autostainer and blocked
with serum-free protein block solution (Dako #X0909)
which was applied for 5 minutes and then FAK primary
antibody (Millipore #05-537) was applied for one hour.
The biotinylated goat anti-mouse IgG (Jackson Immuno
Research Labs, #115-065-062) was applied for 30 minutes,
followed by the Elite ABC Kit (Vectastain, #PK-6200)
for 30 minutes, and the DAB chromagen (Dako, #K4007)
for 5 minutes. The slides were counterstained with
hematoxylin, dehydrated, cleared and cover slipped.Immunohistochemistry scoring for FAK
The scoring was performed by a board-certified pathologist
(L.Y.), as described [14]. The scoring system of triplicate
tumor cores included intensity of staining (0, none; 1+,
weak; 2+, moderate; 3+, strong) plus extent of staining,
which was equal to the number of cores with a positive
staining (extent 0, no staining in three cores; 1, only one
core had a positive staining; 2, only 2 cores had a positive
staining; 3, all three cores had the positive staining). Thus,
the score ranged from 0 to 6 and included the average
intensity and extent of staining.
Statistical methods
The associations between FAK scores and categorical
factors were assessed using independent sample permu-
tation t-test. Patients with less than two tissue sample
Golubovskaya et al. BMC Cancer 2014, 14:769 Page 3 of 8
http://www.biomedcentral.com/1471-2407/14/769cores were excluded from analysis. The median FAK
score was used to dichotomize patients into FAK high
and FAK low categories. A Cutoff value of 4.0 that was
equal to median FAK score in 196 primary tumors was
used for tumor classification and patient dichotomizing
into two groups. The same cut-off for patient dichotom-
izing into two groups was used for 117 matched primary
and metastatic tissues. Fisher’s Exact and the Wilcoxon
Rank sum test were used for categorical and continuous
comparisons between dichotomous FAK categories. The
Spearman correlation analysis was performed in 117
matched primary and metastatic tissues. Normal and
Kernel distribution was performed on these samples for
FAK expression. Kaplan Meier curves and Logrank test
were used for Overall Survival (OS) and progressionFigure 1 Immunohistochemical analysis of FAK expression in breast canc
staining with FAK 4.47 monoclonal antibody of TMA samples with triplicate ti
pathologist using the following scoring system that measured intensity: (0, no
positive staining; 1, one core has positive staining score; 2, two cores have po
score was calculated by adding the average intensity and extent of staining a
staining from 0 to 3+ is shown in breast samples. The intensity from 0 to 3 isfree survival (PFS) data. The p-value less than 0.05, was
considered statistically significant.
Results
TMA’s contained breast tumor samples from 196 patients
with a median age of 56 years, range 27 - 91 years
(Table 1). The median number of resected lymph nodes
was 19 and median number of positive lymph nodes 4.
68.2% of women had stage II disease and 31.8% had stage
III or IV disease (Table 1).
FAK expression was determined by immunohisto-
chemical staining of the TMA’s tumor tissues, which
contained in triplicate three 1 mm cores of each tumor
sample. We used the scoring system from 0 to 6, which
quantified the average intensity of staining and extenter TMA samples. FAK expression was detected by immunohistochemical
ssue cores per tumor stained. The slides were scored by a board-certified
ne; 1+, weak; 2+, moderate; 3+, strong) (A) and extent of staining (0, no
sitive staining; and three cores have positive staining (B). The staining
nd the core ranged from 0 to 6. Upper panel: different intensity of
shown on A and extent from 1 to 3 is shown on B panel.
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(Materials and Methods). The tumor intensity levels
from 0 to 3 are shown in Figure 1A and extent from 1
to 3 on Figure 1B. We dichotomized FAK expression in
two groups based on the median FAK staining score in
tumors, which was equal to 4 (Figure 2, left panel). One
group included tumors with high FAK expression (>4
score) and another group included tumors with low
FAK expression (≤4 score) (Table 2). High FAK expression
was observed in 27% of patients and low FAK expression
was observed in 73% of patients (Table 2).
High FAK expression in primary tumors was associated
with younger patient age (the median age was 51 versus
57 with low FAK expression) (p = 0.033) (Table 2). The
median number of positive lymph nodes was higher in the
group with high FAK: 5.0 versus 3.0 (p = 0.062). There
were no statistically significant differences between FAK
expression and stage and tumor grade. There were no
significant associations between ER negative, PR-negative
or Her-2 positive phenotype , but there were significant
associations of high FAK expression with triple-negative
phenotype (p = 0.033). There was also a highly significant
association of high FAK expression with lymphovascular
invasion (LVI) (p = 0.001) (Table 2).
Of the overall 196 patients with primary tumor samples,
there were 117 who also had matched metastatic tumors
samples. Although these 117 primary tumor samples
had higher percentages of being ER and PR negative,
HER2 positive, triple negative and having LVI comparedFigure 2 Distribution of FAK staining in primary tumors. The
medium FAK staining is equal to 4 in primary tumors. The primary
tumors were divided for analysis on two groups higher than
medium >4 and ≤4 (Table 2).to the overall group of 196, this did not reach statistical
significance (not shown). We performed analyses of FAK
expression in the 117 metastatic tumors that were avail-
able for 117 matched primary tumors (Figure 3A). The
median score of FAK expression in 117 primary tumors
was 3.5 and the median score in matched metastatic
tissues was 2.67. Among 117 patients 27 (23%) had FAK
score in primary tumors equal to 0, and among these 27
patients with FAK-negative primary tumors 11 (40.7%)
had increased FAK expression in metastatic tumors and
16 (59.3%) had score equal to 0 in metastatic tumors. The
FAK scores in these metastatic tumors ranged from 1.33
to 6 with mean score equal to 1.2 versus 0 in primary
tumors, p < 0.01. The distribution of FAK expression in
primary and metastatic tissues is shown in (Figure 3A,
upper and lower panels). We dichotomized patients into
two groups with the same criteria as used for 196 patients
in Table 2, high FAK > 4 and low FAK ≤4 and performed
correlation between FAK expression and patient clinical
data. Although, there were no statistically significant
correlations between FAK expression and patient clin-
ical data in the metastatic samples (not shown), there
was a positive Spearman correlation between high FAK
expression in primary and metastatic tissues (r = 0.45;
p < 0.0001) (Figure 3B). The patients with higher FAK
expression in primary tumors expressed higher expression
of FAK in metastatic tumors (Figure 3B).
Moreover, we performed correlation analysis of FAK
expression in matched primary and metastatic tumors
with progression free survival (PFS) and overall survival
(OS). Figure 3C shows the Kaplan-Meier overall survival
and progression free survival curves in primary and
metastatic tumors. Although there was a trend towards
a worse outcome, there was no statistically significant
difference between high FAK expression in primary tumors
and PFS and OS. The median overall survival of patients
with FAK score >4 in primary tumor was 80 months from
diagnosis, while those with FAK score ≤4 was 123.0 months
(logrank p-value = 0.0875). The same was observed with
progression free survival that was equal to 42.6 months in
patients with high FAK expression versus 107.9 months
with low FAK expression (logrank p = 0.2) (Figure 3C,
left panels). In contrast, there was a strong statistically
significant difference between high FAK expression and
PFS and OS in patients with metastatic samples (Figure 3C,
right panels). The progression free survival in patients with
high FAK expression (FAK > 4) in metastatic tissues was
35 months, while PFS in patients with low FAK expression
in metastatic tumors was 110.9 months (logrank p = 0.002).
The overall survival in patient with high FAK expression
in metastatic tumors was 44 months versus 123 months in
patients with low FAK expression, (logrank p = 0.003).
Thus, although there was no correlation between FAK
expression in primary tumors, there was a strong positive
Table 2 Correlation between FAK expression and clinicopathological characteristics in primary tumors
Characteristic FAK ≤ 4 low FAK > 4 high Total number P-value
Number of cases 143 (73%) 53 (27%) 196
Age (median) 57 51 56 0.033
Positive Lymph nodes (median) 3.0 5.0 4.0 0.062
Histological grade
Grade I (well differentiated) 7 (5.2%) 7 0.143
Grade II (moderately differentiated) 23 (17.0%) 13 (24.5%) 36
Grade III (poorly differentiated) 105 (77.8%) 40 (75.5%) 145
Stage
Stage IIA 48 (33.8%) 10 (18.9%) 58 0.124
Stage IIB 52 (36.6%) 23 (43.4%) 75
Stage IIIA 12 (8.5%) 11 (20.8%) 23
Stage IIIB 20 (14.1%) 6 (11.3%) 26
Stage IIIC 3 (2.1%) 1 (1.9%) 4
Stage IV 7 (4.9%) 2 (3.8%) 9
Estrogen receptor (ER)
Positive 115 (81.6%) 40 (75.5%) 155 0.346
Negative 26 (18.4%) 13 (24.5%) 39
Progesterone receptor (PR)
Positive 86 (61.0%) 26 (49.1%) 112 0.134
Negative 111 (79.3%) 41 (77.4%) 152
HER-2
Positive 29 (20.7%) 12 (22.6%) 41 0.770
Negative 111 (79.3%) 41 (77.4%) 152
Triple negative status
No 126 (90.6%) 42 (79.2%) 168 0.033
Lymphovascular invasion (LVI)
No 75 (56.8%) 16 (30.8%) 91 0.001
Yes 57 (43.2%) 36 (54.4%) 93
The statistical significant correlation is marked by bold font.
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and OS in patients with metastatic tumors that may be
very important for clinical studies.
Discussion
Overexpression of FAK has an important role in tumori-
genesis, tumor survival, and metastasis. This paper high-
lights a method of accurately measuring FAK expression
using TMA technique, allowing direct comparison of FAK
expression in multiple tissue samples. The prognostic value
of FAK and its associated clinicopathologic characteristics
is important for development of new and more effective
treatment regimens for breast cancer patients, especially as
FAK inhibitors enter clinical trials.
A recent report that analyzed FAK expression in 98
breast tumor samples using TMA analysis did not show a
significant association with FAK and prognostic indicatorsin breast cancer [15]. That study used a different FAK
antibody (rabbit polyclonal against phospho Y397 FAK)
[13] in contrast to the FAK 4.47 monoclonal antibody
used in this study, which was shown before to be highly
specific to FAK [4]. In addition, the present study exam-
ined almost two times more breast cancer samples,
used each tumor in triplicate, and the scoring system of
triplicate samples included not only the average intensity
but also the extent of staining, allowing for more accurate
analysis. The distribution of high FAK expression being
observed in 27% of patients and low FAK expression in
73% of patients in this paper is consistent with the
findings of previous reports and validates this method
of analyzing FAK expression (11).
Our previous report [11] demonstrated an association
between high FAK expression and overexpression of
Her-2, while this report did not. This difference may
Figure 3 Analysis of FAK expression in primary tumors and matched metastatic tissues. A. Distribution of FAK expression in 117 primary
and matched metastatic tissues. Upper and lower panels show distribution of FAK expression in primary and metastatic tissues (N = 117). The
median FAK expression in primary tumors is equal to 3.5 and in metastatic tissues 2.67 (N = 117). Normal (marked by solid line) and Kernel
(marked by dotted line) distribution of FAK expression in both groups are shown. Wilcoxon Exact p-value = 0.024. B. Correlation between FAK ex-
pression in primary and metastatic tissues. The positive Spearman correlation between FAK expression is shown. Correlation coefficients are
shown on left lower panel. C. Overall survival and progression free survival in patients with matched primary and metastatic breast cancer tumors.
Left panels: Progression-free survival and overall survival (OS) curves in patients with primary tumors with high FAK (FAK > 4) compared to low
FAK expression (FAK≤ 4). Right panels: Progression-free survival curve and overall survival curves in patients with metastatic tumors. There is a
strong correlation between high FAK expression in metastatic tumors and shorter PFS and OS. Logrank p < 0.05.
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reports there are differences in the stage of tumors that
were analyzed. While the present report did not include
patients with stage I disease and instead analyzed patients
with stage II (68.2%) and stages III and IV (31.8%) breast
cancer, the previous report analyzed patients at earlier
stages and included 39% of patients with stage I, 50%
with stage II, and only 11% patients at stage III and IV
disease. Therefore, correlation of high FAK and Her-2
was observed at earlier stage of disease, but not at later
stage of disease. Second, the smaller sample size in this
report compared to the prior report (196 vs 629 patients)may have impacted the results of the Her-2 association.
Lastly, the way in which FAK levels were scored in this
paper differs from that of previous reports potentially
contributing to these differences.
Although a significant association was not found between
FAK and Her-2 in this paper, there is evidence that FAK
and Her-2 signaling pathways are linked in breast cancer
development. Activated FAK colocalized with Erb-2/3
receptors at cell protrusions and FAK signaling had an es-
sential function in ErbB-induced invasiveness, metastasis
and oncogenesis [16]. A recent report addressed the issue
of anti-Her-2 agent resistance in breast cancers where
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Her-2 with trastuzumab in ER+/Her-2+ patients showed
synergistic effect on the suppression of cell growth and
improved the response to trastuzumab [17].
This report for the first time demonstrated high levels
of FAK in triple-negative breast cancer patients and cor-
related with shorter overall survival of the triple-negative
group (not shown). This association can be important for
the development of therapies for triple-negative breast
cancer, suggesting an important role of FAK in triple-
negative breast cancer survival signaling. This data is
consistent with previous data on increased FAK gene
amplification by FISH analysis in triple-negative breast
cancer tissues [18]. Since triple-negative breast cancer
tumors tend to be more aggressive and result in a worse
prognosis, more effective therapies are needed in this
population of patients [19]. Emerging data show that FAK
can be an effective therapeutic target in tumors, especially
in highly aggressive triple-negative breast cancer tumors.
In fact, we tested MDA-231 triple-negative breast cancer
cells with FAK autophosphorylation inhibitor [6,20,21]
and showed that this FAK inhibitor significantly decreased
cancer cell viability and clonogenicity in vitro (not
shown). Thus, these data suggest that targeting FAK in
triple-negative breast cancer patients is a promising
approach. It is important to note that FAK has many
binding partners and integrates multiple oncogenic
survival pathways and sequesters tumor-suppressor path-
ways [1,22]. Therefore, future therapeutics should involve
multiple targets cross-linked with FAK survival signaling
in breast cancer tumors, and especially in aggressive
triple-negative breast cancer tumors.
The data on association of high FAK expression in pri-
mary breast cancer tumors with lymphovascular invasion
supports the important role of FAK in epithelial and mes-
enchymal transition [23], angiogenesis, lymphangiogenesis
[24] and metastasis [25]. We detected correlation between
high FAK expression and lymphovascular invasion, which
is consistent with the role of FAK in metastasis and angio-
genesis/lymphangiogenesis. The association of high FAK
expression and lymphovascular invasion in tumors corre-
lated with worse patient prognosis and lower overall
survival. Metastasis of breast cancer occurs mainly through
lymphatic system and the dissemination of tumor cells to
the regional lymph nodes is an indicator of breast cancer
aggressiveness [26]. The recent study found that LVI was
significantly associated with predicting patient outcome
leading to shorter breast cancer specific survival as well as
distant metastasis-free survival [27].
Interestingly, we detected high level of FAK in meta-
static samples with the median score FAK staining equal
to 2.67, which was lower than in primary tumors (median
score in 117 primary tumors was 3.5 (Figure 3). While
we did not find correlation between clinicopathologicaldata such as hormone receptor status, triple-negative
phenotype or LVI in metastatic tissues that were identified
in the matched primary tumor samples, we did find
correlation between high FAK expression in primary
tumors and metastatic tissues. In addition, among 117
patients 23% had FAK-negative primary tumors, and
among these more than 40% increased FAK in metastatic
tumors confirming important role of FAK in metastasis.
Although the median level of FAK was not increased
in metastatic tissues compared to the matched primary
tumors, we found a strong positive correlation between
high FAK expression in metastatic samples and shorter
progression-free survival and overall survival that was
not observed in the primary tumors. The overall survival
of patients with high FAK expression was almost 3-fold
shorter (44 months versus 123 months from diagnosis)
than in patients with low FAK expression. These data
support the important role of FAK in metastasis.
Conclusions
The present simultaneous analysis of FAK expression
using tissue microarrays allows for a more comprehensive
method of analyzing FAK expression in breast tumor
samples. This analysis demonstrated the prognostic
value of high FAK expression in breast tumors being
associated with more aggressive tumor features such as
lymphovascular invasion and triple-negative phenotype.
In addition, a high positive correlation between high
FAK expression in primary tumors and metastatic tissues
was shown, with significantly worse overall and progression
free survivals found in patients whose metastatic tumors
had high FAK expression. These associations are important
for understanding the mechanisms of breast tumorigenesis
and for the development of novel biomarkers associated
with FAK overexpession and new, effective anticancer
therapies.
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